Rapid Communications |
From the Vascular Biology Unit (R.M., R.F., J.E.C., C.J.G.), Department of Surgical Research, Northwick Park Institute for Medical Research, Harrow, Middlesex, UK, and the Department of Medicine (A.G., R.M.W.), VA Medical Center, University of California San Diego, La Jolla, Calif.
Correspondence to Dr Roberto Motterlini, Vascular Biology Unit, Department of Surgical Research, Northwick Park Institute for Medical Research, Harrow, Middlesex, HA1 3UJ UK. E-mail r.motterlini{at}ic.ac.uk
| Abstract |
|---|
|
|
|---|

Hb, a chemically
modified hemoglobin known to scavenge NO, and (2)
NG-nitro-L-arginine methyl ester
(L-NAME), a competitive NOS inhibitor. Experiments were
carried out in conscious rats in which femoral arteries and veins were
surgically catheterized 1 or 5 days before treatment with the
vasoconstrictor agents. Intravenous infusion of 
Hb
(8% solution) or L-NAME (30 mmol/kg) produced an acute and
significant increase in mean arterial pressure
(P<0.05) in rats at 5 days after catheter implantation.
In contrast, no change in blood pressure was observed when 
Hb or
L-NAME was infused 1 day after the surgical intervention. The
suppression of the hypertensive response observed at 1 day after
surgery correlated with a significant (P<0.05) HO-1
expression in aorta, heart, and liver as well as increased aortic CO
production and cGMP levels. At 1 day after surgery,
pretreatment of animals with the heme oxygenase
inhibitor zinc protoporphyrin IX (50 µmol/kg IP)
markedly decreased aortic CO and cGMP levels and completely restored
the vasoconstrictor effects of both 
Hb and L-NAME. These results
provide evidence for a crucial role of the heme
oxygenase/CO pathway in the regulation of blood pressure
under stress conditions in vivo.
Key Words: surgical stress hemoglobin-based blood substitute carbon monoxide bilirubin cGMP
| Introduction |
|---|
|
|
|---|
-methene
carbon bridge of the porphyrin ring as CO.1 The
subsequent step in heme catabolism occurs in the cytosol with the
conversion of biliverdin to bilirubin by the enzyme biliverdin
reductase. Heme oxygenase is a ubiquitous protein and
exists in 2 different isoforms that are products of 2 different
genes.2 The heme oxygenase-2 (HO-2)
isoform is constitutively expressed and is found at high levels
primarily in the brain and testes.1 In contrast,
the heme oxygenase-1 (HO-1) isoform is inducible and is
regarded as a heat shock protein (HSP32), the expression of which is
markedly upregulated by stress-related conditions that alter the redox
status of the cellular milieu. Several pro-oxidant factors and agents,
including heat shock,3
endotoxin,4 heavy metal
ions,1 5 and ultraviolet
irradiation6 have been reported to increase HO-1
expression and activity in a variety of tissues. The precise
physiological significance of HO-1 induction under
stress conditions still remains to be elucidated. The hypothesis has
been postulated that the expression of this gene is part of the
defensive mechanism that cells and tissues are capable of mounting
against different stress stimuli.5 7
Consistent with this notion are the findings that biliverdin
and bilirubin, end products of heme catabolism, possess antioxidant
properties8 and that CO seems to mimic many NO
functions.9 NO is enzymatically synthesized from L-arginine by NO synthase (NOS), which, similar to heme oxygenase, exists in constitutive (cNOS and nNOS) and inducible (iNOS) isoforms.10 NO is a free radical gas that possesses multiple biological functions and has been identified as endothelium-derived relaxing factor.11 12 The basal release of NO, observed during resting conditions in vascular endothelial cells, mediates the relaxation of smooth muscle via activation of a heme-dependent guanylate cyclase that catalyzes the conversion of GTP to the second-messenger cGMP. This transduction mechanism mediated by NO is responsible for the maintenance of vascular tone and is fundamental to the regulation of blood pressure in mammals.13 14 CO has also been reported to activate guanylate cyclase in smooth muscle cells, although its affinity for the heme moiety of guanylate cyclase is much lower than that associated with NO.15 Similar to NO, CO derived from heme oxygenase has been postulated to act as a neurotransmitter,16 17 and recent findings have demonstrated the participation of CO in the regulation of vascular tone in hepatic sinusoidal cells, suggesting that NO and CO could share the control of relaxation processes.18 CO has been demonstrated to function as an endogenous modulator of the NO-cGMP signaling system in the brain. In cultured cerebellar granule cells, the NO-mediated cGMP increase is blocked by augmenting endogenous CO production and potentiated by inhibitors of the heme oxygenase pathway.19 In vitro and in vivo studies conducted in our laboratory and other laboratories have demonstrated that NO is also capable of increasing HO-1 expression and activity in vascular20 21 22 23 and liver tissues,24 25 emphasizing the importance of heme oxygenase as a target/stimulator of signal transduction mechanisms.
Vascular tone and blood pressure are controlled at various levels by a series of systems that involve a complex interaction between homeostatic factors, including the renin-angiotensin system, the autonomic nervous system, and, as mentioned above, the release of local mediators such as endothelium-derived relaxing factor/NO. Although the administration of inhibitors of NOS activity, such as NG-nitro-L-arginine methyl ester (L-NAME), has been extensively used to produce vasoconstrictor effects in various species in vivo,14 only limited information is available concerning the possible role of the heme oxygenase/CO pathway in the control of blood pressure. Johnson et al26 have recently reported that administration of zinc protoporphyrin IX (ZnPPIX), a potent heme oxygenase inhibitor, causes an increase in arterial pressure in rats. This effect was attributed to blockade of the inhibitory action of endogenous CO on a pressor mechanism that is mediated by the autonomic nervous system. However, no direct link has been established between the level of tissue heme oxygenase, its activity in terms of CO production, and its role in the regulation of pressor responses in animal models.
The present study was designed to investigate the potential contribution of stress-mediated HO-1 induction to the modulation of hypertensive responses caused by inhibitors of the NOS/NO system in conscious rats. We report herein that increased CO release after upregulation of tissue HO-1 is a determinant factor in the control of blood pressure under stress conditions in vivo. The biochemical and physiological relevance of these findings will be discussed.
| Materials and Methods |
|---|
|
|
|---|
chains at
-Lys99 (
Hb) was obtained from Letterman
Army Institute of Research (San Francisco, Calif) and was prepared by
reacting human stroma-free hemoglobin with
bis(3,5-dibromosalicyl)fumarate as previously
described.27 
Hb was stored as oxyhemoglobin
in sealed foil containers at -80°C until use. Bovine hemoglobin was
obtained from Sigma Chemical Co, and deoxyhemoglobin was prepared by
using sodium dithionite as previously
described.28 ZnPPIX was purchased from Porphyrin
Products and dissolved in 50 mmol/L sodium bicarbonate
immediately before use. L-NAME was from Sigma, and
3-morpholinosydnonimine (SIN-1) was kindly provided by Dr R. Henning
(Cassella A.G., Frankfurt, Germany). Both L-NAME and SIN-1 were
dissolved in 0.9% saline immediately before intravenous
injection. [2-14C]L-Glycine was
purchased from ICN. All other reagents used were from Sigma unless
otherwise specified.
Animal Preparation
Male Sprague-Dawley rats (300 to 350 g) were purchased from
Harlan Sprague Dawley Laboratories, Inc (San Diego, Calif) and housed
at constant temperature (23°C) in rooms that provided automatic
lighting with a 12-hour on-off cycle. Rats were acclimatized for 2 to 3
days in plastic cages and were given free access to water and food. On
the day of surgery, animals were anesthetized with an
intramuscular injection of the following mixture: 0.5%
ketamine/0.4% acepromazine/1% xylazine (0.2 mL/100 g body
wt). Specially designed femoral artery and venous catheters were then
surgically implanted as previously
described.29 30 Rats were then returned to the
plastic cages and allowed to recover from the surgical procedure for
the time indicated in the experimental protocol. Both femoral arteries
and one femoral vein were cannulated in rats undergoing isovolemic
exchange transfusion with 
Hb, whereas animals receiving bolus
injections of NOS inhibitor/NO donor had only one
arterial and one venous catheter implanted in opposite
legs. The basic design for this chronic catheter implantation technique
was optimized to improve longevity and patency in studies requiring
vascular access for up to 7 days after cannulation.
Experimental Protocols
All in vivo experiments were performed on previously
instrumented and fully conscious rats that were given a brief (1-day)
or prolonged (5-day) postsurgical recovery period. On the day of
experimentation, awake rats were placed in a restrainer (Braintree
Scientific Inc), and one arterial line was connected to a
pressure transducer (UFI model 1050) for continuous mean
arterial pressure monitoring, and data were recorded
using a Biopac MP100 system with AcqKnowledge software (BIOPAC System
Inc). In the first and second group of animals (1 and 5 days after
surgery, respectively; n=5 each), a 50% isovolemic exchange
transfusion with 
cross-linked hemoglobin (
Hb) was carried
out using a 2-channel peristaltic pump (Labconco Corp). 
Hb is a
chemically modified hemoglobin that is currently being investigated as
a potential oxygen carrier and has been shown to induce acute systemic
hypertension in a similar animal stress
model.29 30 Removal of blood from the
arterial line and intravenous infusion of

Hb solution (8%) were performed simultaneously at
identical flow rates (0.5 mL/min). The 
Hb solution was sterilized
before infusion by filtration through a 0.2-µm filter (Millipore) and
warmed to 37°C in a water bath. In a third and fourth group of
experiments, animals (1 and 5 days after surgery, respectively; n=5
each) were given an intravenous injection of 30
mmol/kg L-NAME, followed 1 hour later by administration of SIN-1
(30 mmol/kg), an organic compound that spontaneously releases NO,
hence causing vasorelaxation. In complementary experiments conducted in
rats at 1 day after surgery, a selective inhibitor of heme
oxygenase activity (ZnPPIX, 50 µmol/kg IP) was
injected intraperitoneally 10 minutes before
infusion of 
Hb or L-NAME (n=5 for each group). A control group
received ZnPPIX (50 µmol/kg IP) alone. Mean arterial
pressure was continuously monitored before and after injection with the
various materials. Because ZnPPIX is light sensitive and has been
reported to have effects unrelated to heme oxygenase
inhibition when exposed to light,31 we carefully
protected this drug from light during its preparation.
Determination of Hepatic and Renal Heme Oxygenase Activity
In another set of experiments, heme oxygenase
activity was determined in rat kidney and liver microsomes at different
time points (1.5 and 12 hours and 1, 2, 3, 5, and 7 days) after
catheter implantation and compared with the activity in control rats
not subjected to any surgical intervention (time 0) (n=5 for each
group). Microsomes were prepared by ultracentrifugation
as previously described.25 32 A portion of the
microsomal fraction was lysed by the addition of PBS buffer containing
1% Triton X-100 and stored at -80°C for Western blot
analysis. The remaining microsomes were resuspended in 1 mL of
0.1 mmol/L potassium phosphate buffer, pH 7.4, containing 2
mmol/L MgCl and analyzed for heme oxygenase
activity by a spectrophotometric assay that measures the formation of
bilirubin, the end product of heme degradation, as previously
described.25
Western Blot Analysis
Liver microsomes were prepared as reported above. Aorta and
heart tissues were homogenized in 1 mL of lysis buffer
(50 mmol/L HEPES, 5 mmol/L EDTA, 50 mmol/L NaCl, and 1%
Triton X-100, pH 7.5) containing Complete protease
inhibitor (Boehringer Mannheim). Samples were kept
on ice for 1 hour and then centrifuged (4°C) for 30 minutes
at 12 000g. After the precipitated unsolubilized fraction
was discarded, the protein concentration was determined in the
supernatant by the Lowry method. Aliquots (30 µg) of protein from
each sample were electrophoresed on a 12% SDS-polyacrylamide
gel using a Mini Protean II system (Bio-Rad). The protein samples were
transferred overnight onto a nitrocellulose membrane. Nonspecific
antibody binding was blocked with 3% nonfat dried milk in PBS, pH 7.4,
for 2 hours at room temperature. The membrane was then probed with
polyclonal rabbit anti-rat HO-1 antibody (StressGen) (1:1000 dilution
in Tris-buffered saline, pH 7.4) for 2 hours at room temperature. After
3 washes with PBS containing 0.05% (vol/vol) Tween 20, blots were
visualized with the use of an amplified alkaline phosphatase kit
(Extra-3A, Sigma). The relative band densities were analyzed
with the use of an imaging densitometer (model GS-700) with Molecular
Analyst software (Bio-Rad).
Measurement of 
Hb Disappearance in Plasma
Plasma heme concentration was used as an indirect index of the
rate of heme catabolism in tissues after exchange transfusion with

Hb. Arterial blood (50 to 100 µL) was collected in
heparinized microhematocrit tubes (n=4 or 5 for each group) at 1, 2,
and 3 hours after the exchange transfusion in animals at 1 and 5 days
after surgery. Samples were centrifuged, and total hemoglobin
content was determined in the plasma fraction by using a
spectrophotometric method that measures azide-methemoglobin
complexes.33 The absorbance was read with the use
of a hemoglobin photometer (Hemocue AB) at 2 different wavelengths (570
and 880 nm) in order to compensate for turbidity. The rate of heme
metabolism from plasma was calculated by measuring the
change in total plasma hemoglobin concentration over time and
determining the slope of the resultant linear plot. The data were
expressed as a fraction of the initial concentration of total plasma
hemoglobin taken at 1 hour after the beginning of 
Hb infusion,
since 30 to 40 minutes was required to complete the exchange
transfusion. To determine the direct involvement of tissue heme
oxygenase in hemoglobin catabolism, plasma hemoglobin
concentration was also measured after transfusion with 
-Hb in
animals (1 day after surgery) pretreated with the heme
oxygenase inhibitor ZnPPIX (50
µmol/kg).
Measurement of Bilirubin in Urine
Bilirubin levels were determined spectrophotometrically with the
use of a diagnostic kit (550-A, Sigma). Surgically
catheterized rats were placed in metabolic cages, and urine
was collected at different times after surgery. The rate of urinary
bilirubin produced over time was expressed in milligrams per hour.
14CO Production in Aortic Tissue
We specifically designed an appropriate device for measuring CO
released from aortic tissue (R. Motterlini, unpublished data).
Two plastic syringes were positioned vertically facing each other and
were connected by a 0.4-µm filter (Millipore) to create 2 separate
chambers. The lower chamber contained 5 µCi of
[2-14C]L-glycine, a heme precursor,
and the upper chamber contained a solution of deoxyhemoglobin (15
µmol/L), which is known to avidly bind CO. Aortas were removed from
rats at various times after surgery, trimmed of adventitial tissue, and
transferred into the lower chamber containing
[2-14C]L-glycine in
oxygenated Krebs-Henseleit buffer (1:20 [vol/vol])
containing (mmol/L) NaCl 118, KCl 4.7,
KH2PO4 1.2,
MgSO4 · 7H2O 1.2,
NaHCO3 22, glucose 11, potassium EDTA 0.03, and
CaCl2 2.5, pH 7.4. With the use of a piston
syringe, a 1-cm air space was left in the lower chamber between the
solution containing the radiolabeled material and the filter. This
enabled the 2 solutions to be kept physically separated and, at the
same time, allowed the diffusion of gas (CO) between the chambers. The
lower chamber was then immersed in a water bath at 37°C for 9 hours
to allow incorporation of
[2-14C]L-glycine into the aortic
tissue. At the end of the incubation period,14CO
bound to hemoglobin was measured in the upper chamber by scintillation
counting (Beckman liquid scintillation counter, model LS6500). The
radioactivity incorporated in the tissue was also measured after
repeated washes of aortas with distilled water.
14CO production was measured in counts
per minute (cpm) and expressed as a fraction of the total
14C incorporated in the aorta by using the
following formula: {14COcpm in the
upper
chamber/(14CO+[2-14C]L-glycine)cpm
in aorta}x10-7/mg tissue.
Determination of cGMP Levels
Levels of cGMP were measured in tissue extracts with the use of
a commercial radioimmunoassay [125I] kit (Du
Pont) and an ELISA kit (Amersham). Tissues were collected from the
following groups of animals: control animals (no surgery); animals at 1
and 5 days after surgery; and animals at 1 day after surgery treated
with L-NAME (30 mmol/kg body wt, bolus injection), ZnPPIX (50
µmol/kg), or L-NAME plus ZnPPIX 10 minutes before tissue harvest. At
the end of each protocol, samples were immediately freeze-clamped in
liquid nitrogen and stored at -80°C until the cGMP assay was carried
out. Duplicate measurements were performed on all samples (n=4 or 5 per
group), including the standard curve.
Statistical Analysis
All values are expressed as mean±SE. Differences in the data
among the groups were analyzed by 1-way ANOVA combined with the
Bonferroni test. A value of P<0.05 was considered
significant.
| Results |
|---|
|
|
|---|

Hb treatment and that, in some
circumstances, the expected hypertensive effect of these 2
vasoconstrictor agents was completely absent. After a series of
preliminary experiments, we found that this variability in the pressor
response was dependent on the time at which the experiment was carried
out after catheter implantation. As shown in Figure 1
Hb (Figure 1A
Hb or L-NAME treatment
did not significantly change mean arterial pressure when
experiments were conducted in rats that were given only a
1-day postsurgical recovery period (130±3.1 versus 132±4.5
mm Hg and 122±3.5 versus 138±8.3
mm Hg, respectively). These findings suggest that
"postsurgical stress" may influence local pressor mechanisms
involved in the regulation of systemic blood pressure. It is
interesting to note that 1 hour after L-NAME treatment a bolus
injection of SIN-1, an organic NO-releasing agent, produced a marked
vasodilatory effect in both groups, indicating that NO-dependent
mechanisms that control vessel tone were not impaired by surgical
stress. Moreover, the suppression of pressor responses was not observed
immediately after surgery (0-day surgery). In experiments conducted at
1.5 hours after surgery in fully conscious rats, administration of

Hb or L-NAME produced an increase in blood pressure from 93±3.9
to 135±2.7 mm Hg and from 90.8±4.2 to 150.5±1.4 mm Hg,
respectively. It needs to be pointed out that the baseline mean
arterial pressure in these groups was
40 mm Hg
lower than the baseline blood pressure in animals at 1 day after
surgery. This is due to the fact that immediately after surgery the
animals, although fully awake, were still under the effect of
anesthesia.
|
Surgical Stress Increases Tissue Heme Oxygenase
Activity and HO-1 Expression
The finding that the pressor response to 
Hb or L-NAME
infusion varied considerably at different times after surgery (1 and 5
days) prompted us to search for a possible mechanism in the regulation
of blood pressure mediated by surgical stress. On the basis of previous
reports showing that surgical procedures cause specific and
simultaneous heat shock protein (HSP) induction in various
tissues,34 we investigated whether the catheter
implantation technique used in our protocol could affect the activity
and expression of HO-1, a small molecular weight stress protein (HSP32)
that degrades heme to biliverdin and CO. Figure 2A
shows the time course of heme
oxygenase activity in kidney and liver at different time
points after the surgical intervention. Hepatic heme
oxygenase activity significantly increased from control
(874±62 pmol bilirubin/mg protein per hour) after catheter
implantation; the activity was maximal at 1 day after surgery (2191±73
pmol bilirubin/mg protein per hour, P<0.05) and started to
diminish gradually at 2 days after surgery (1540±141 pmol bilirubin/mg
protein per hour, P<0.05). Heme oxygenase
activity returned to control levels by 3 days after surgery (907±76
pmol bilirubin/mg protein per hour) and remained unchanged up to 7 days
after catheter implantation. No significant changes in renal heme
oxygenase activity were detected after surgery at the time
points considered. A possible effect of the anesthetic in the
modulation of the stress response (HO-1 induction) can be excluded
a priori, since anesthetized rats not subjected to surgery
or immediately after surgery (1.5 hours) showed no increase in hepatic
heme oxygenase activity (data not shown). The increase in
hepatic heme oxygenase activity after surgery was reflected
in an increase in the inducible isoform of this protein (HO-1) in
liver, heart, and aorta, as shown by Western immunoblot
analysis (Figure 2B
and 2C
). A recent observation showed that
transfusion of 
Hb in a similar animal model produced an increase
in mean arterial pressure at 1 day after
surgery.35 However, a direct comparison with the
present study is difficult to make, since in that
study35 no measurements of heme
oxygenase activity and HO-1 expression were performed in
any tissue after surgery.
|
Effect of ZnPPIX on Blood Pressure at 1 Day After Surgery
We used ZnPPIX, a selective inhibitor of heme
oxygenase, to establish the direct involvement of HO-1
induction in the control of pressor responses after surgical stress.
Injection of ZnPPIX before transfusion with 
Hb or L-NAME
treatment resulted in a rapid increase in blood pressure in rats at 1
day after surgery (from 121±5.7 to 149±2.7 mm Hg and from
122±4.3 to 162±5.7 mm Hg, respectively; P<0.05)
(Figure 3A
and 3B
), whereas 
Hb or
L-NAME alone did not produce a significant vasoconstrictor effect
(Figure 1A
). The hypertensive effect mediated by L-NAME was sustained
for 1 hour and then completely reversed by a bolus injection of the
NO-releasing agent SIN-1, as shown by a significant drop in mean
arterial pressure from 159±3.3 to 87±3.1 mm Hg
(P<0.05) (Figure 3B
). It has to be noted that 50
µmol/kg of ZnPPIX alone did not have any significant effect on mean
arterial pressure in rats at 1 day after surgery, when heme
oxygenase activity and HO-1 protein were at maximal levels
(Figure 3A
).
|
Heme Catabolism Is Accelerated After HO-1 Induction by
Surgical Stress
Since the rates of autoxidation and release of heme from 
Hb
are much higher than from unmodified
hemoglobin,36 we assumed that the presence of

Hb in plasma would augment heme absorption and catabolism by
vascular and organ tissues. If that is the case, then the half-life of
plasma hemoglobin in the systemic circulation would be expected to vary
as a function of the activity of tissue heme oxygenase, the
enzyme responsible for heme breakdown. Total plasma hemoglobin
concentration was measured at various time points after transfusion
with 
Hb in rats at 1 and 5 days after surgery. The half-life of

Hb in plasma (time at which the concentration of 
Hb is 50%
of its initial value) has been previously determined by using a similar
animal stress model and has been reported to be in the range of 4.5 to
5.5 hours.30 The rate of metabolism
of heme circulating in plasma in the various groups is
represented in Figure 4
, and the half-life of hemoglobin disappearance was calculated from the slope
of each linear plot. Plasma hemoglobin disappearance was significantly
(P<0.05) faster in rats that were transfused at 1 day after
catheter implantation (half-life of 3.4 hours) compared with rats
transfused at 5 day after surgery (half-life of 4.4 hours). In
experiments conducted at 1 day after surgery, pretreatment of animals
with ZnPPIX prolonged the retention time of 
Hb in the
circulation, and the half-life increased from 3.4 to 4.1 hours. It is
interesting to note that the rate of heme metabolism in
plasma directly correlated with the level of tissue heme
oxygenase, since heme oxygenase activity and
protein expression (HO-1) were significantly higher at 1 day after
surgery than at 5 days after surgery.
|
Surgical Stress Increases Urinary Bilirubin Production and
CO Formation in Aorta
Surgical stressmediated induction of HO-1 in rat tissues was
associated with a high level of urinary bilirubin, the end product
of heme catabolism. As shown in Figure 5A
, the rate of bilirubin
production in urine markedly increased (P<0.05) at
1 day after surgery from 0.13±0.01 to 0.31±0.03 mg/h and gradually
returned to control values at 5 days after surgery (0.14±0.01 mg/h).
Accordingly, the level of aortic CO, another product of heme
catabolism, directly correlated with the induction of HO-1 mediated by
surgery (Figure 5B
). The release of 14CO from
aortas significantly increased at 1 day after surgery
(P<0.05) but was completely blocked by pretreatment of
animals with ZnPPIX. The increase in CO production after
surgery was temporary and returned to control levels at 5 days after
surgery.
|
Changes in cGMP Levels in Response to Surgical Stress
Recent evidence suggests that heme oxygenasederived
CO interacts with the heme moiety of guanylate cyclase in a
manner similar to NO and may thereby contribute to the regulation of
vascular tone by increasing intracellular levels of the second
messenger cGMP.18 We therefore investigated
whether cGMP is increased after surgical stressmediated activation of
tissue heme oxygenase. As shown in Figure 6
, cGMP significantly increased at 1 day
after surgery in aortic tissue (from 5.6±1.1 to 20.2±2.8 fmol/mg
tissue, P<0.05) and returned to control levels at 5 days
after surgery (6.9±1.7 fmol/mg tissue). At 1 day after surgery,
treatment of animals with L-NAME alone produced a significant decrease
in cGMP to control levels (8.0±0.8 fmol/mg tissue). Similarly, ZnPPIX
suppressed the increase in cGMP, which did not fall below control
levels (8.6±0.4 fmol/mg tissue), suggesting a specific
inhibitory action of ZnPPIX on heme oxygenase
activity rather than on soluble guanylate cyclase activity.
Interestingly, only when the 2 inhibitors were used
simultaneously did aortic cGMP levels markedly diminish
below the control values (1.65±0.l fmol/mg tissue,
P<0.05). In contrast to aortic tissue, hepatic cGMP
significantly decreased at 1 day after surgery and returned to basal
levels at 5 days after surgery (Figure 7
). Furthermore, when the NOS
inhibitor L-NAME was injected intravenously in
rats at 1 day after surgery, hepatic cGMP remained significantly lower
compared with cGMP in control tissues. No significant changes in cGMP
levels were detected in heart (data not shown) and kidney after the
surgical procedure.
|
|
| Discussion |
|---|
|
|
|---|
It is known that hemoglobin avidly binds NO, the
endothelium-derived relaxing factor, with an affinity
much higher than its affinity for oxygen and can be effectively used as
a NO scavenger.14 In our experimental protocol,
we used 
Hb, a hemoglobin cross-linked between
chains, which
is currently investigated as a potential red blood cell
substitute.37 Similar to infusion of unmodified
hemoglobin, infusion of 
Hb in ex vivo and in vivo systems has
been shown to produce coronary vasoconstriction and increase in
arterial blood pressure.37 38 39
Resuscitation with 
Hb during treatment of hemorrhagic shock in a
water-deprived swine model resulted in systemic and pulmonary
hypertension.40 This effect was mimicked by the
NOS inhibitor L-NAME but not by cyanomethemoglobin, which
does not bind NO. In the present study, we unexpectedly found that
a 50% isovolemic exchange transfusion with 
Hb in rats did not
cause any change in mean arterial pressure. This is
apparently in contrast with a previous report by Keipert et
al29 showing that in the same animal model,
transfusion with 
Hb produced an acute increase in systemic blood
pressure. In search of a possible explanation for these contradictory
results, we noticed that Keipert et al conducted their experiments
5
days after femoral artery and venous catheters were implanted to allow

Hb infusion and blood pressure monitoring, whereas in our
experiments the transfusion was performed 1 day after the surgical
intervention.39 If animals were allowed at least
5 days of postsurgical recovery period, we could then observe a
significant increase in blood pressure after the administration of

Hb, as Keipert et al did. This suggests that the time after
surgical procedures is a critical determinant in the manifestation of
the acute hypertensive effect of 
Hb. Moreover, the fact that

Hb, which avidly binds NO with an affinity much higher compared
with O2 or CO, did not produce an increase in
mean arterial pressure at 1 day after surgery indicates
that NO does not significantly contribute to the suppression of the

Hb-mediated hypertensive effect. This was confirmed by
experiments with L-NAME showing that administration of the NOS
inhibitor did not produce any increase in
arterial blood pressure in rats at 1 day after surgery.
These findings indicate that under the particular conditions used in
our protocol, local effector molecules other than NO play a critical
role in the maintenance of the pressor tone. In view of these
data, our experimental model of stress provided a tool for
investigating the biochemical pathway(s), in addition to the NOS
pathway, that may be directly involved in the suppression of
hypertensive responses in vivo.39
We reasoned that the exquisitely sensitive stress protein HO-1 (HSP32)
could be affected in rat tissues by the surgical procedure used for
catheter implantation. In fact, we found that surgical stress
significantly increased the levels of heme oxygenase in
aorta, heart, and liver. The time course of heme oxygenase
activity was paralleled by the time course of HO-1 expression, with
maximum induction of this stress protein being observed at 24 hours
after surgery and gradually decreasing thereafter. This finding is
consistent with a 40-fold increase in HO-1 (HSP32) mRNA
expression observed in all rat organs after brief exposure of animals
to heat shock, another commonly used type of
stress.3 Our results are also in agreement with a
previous report showing that a moderate surgical stress produced a
specific and simultaneous induction of HSP70 in both
parenchymal and vascular tissues.34 Of major
interest is that HO-1 protein expression in vascular tissue reached a
maximum at 1 day after surgery, the time at which the acute
hypertensive response to 
Hb or L-NAME infusion was totally
abolished. The hypertensive effect mediated by these 2 vasoconstrictor
agents was restored in rats at 5 days after surgery (when tissue heme
oxygenase returned to basal levels) or at 1 day after
surgery after treatment with the heme oxygenase
inhibitor ZnPPIX. Thus, an interaction exists between a
cellular stress response and blood pressure regulation, indicating a
direct involvement of HO-1 induction in the modulation of pressor
responses under stress conditions. Our data are in agreement with a
previous report showing that treatment with tin, a powerful inducer of
heme oxygenase, prevented the development of hypertension
in spontaneously hypertensive rats.41 Similarly,
chronic treatment of spontaneously hypertensive rats with heme
oxygenase substrates, heme-L-lysinate and
heme-L-arginate, resulted in a significant lowering of
blood pressure that was blunted by pretreatment with an
inhibitor of heme
oxygenase.42 Therefore, it appears
that conditions characterized by elevated tissue HO-1 are associated
with alterations of the mechanism(s) controlling pressor responses.
It is reasonable to suggest that HO-1derived CO plays a fundamental role in the regulation of pressor responses after surgical stress. Recent reports have demonstrated that CO serves as an important cellular signaling molecule in major organs, such as brain, liver, and heart,16 18 43 and that the HO-1/CO system may be upregulated in vascular endothelial and smooth muscle cells when appropriately stimulated.21 22 44 Similar to NO, CO is an activator of guanylate cyclase and may function as a vasodilator by regulating the intracellular level of cGMP in smooth muscle cells.15 The main endogenous source of CO in mammal tissues derives from the degradation of heme by constitutive heme oxygenase (HO-2), and this accounts for almost 95% of the total CO produced in normal conditions.45 This amount can be increased greatly when inducible HO-1 is upregulated in response to a variety of stressful agents that challenge a particular organ or tissue.5 The results of the present study are consistent with the hypothesis that HO-1, once stimulated, can actively use heme as a substrate for CO production. In fact, we found that stress-mediated induction of tissue heme oxygenase was associated with (1) increased CO and cGMP production in aortic tissues, (2) accelerated metabolism of heme, as measured by an increased rate of plasma hemoglobin disappearance, and (3) increased excretion of urinary bilirubin, the end product of heme catabolism. The increase in aortic CO and the augmented catabolism of heme were significantly attenuated by pretreatment of animals with ZnPPIX. In addition, both CO release and aortic cGMP as well as urinary bilirubin returned to basal levels at 5 days after surgery (when heme oxygenase activity was also back to normal values). It needs to be pointed out that the actual amount of CO released from aortas after surgical stress may be higher than the values measured. In fact, it is possible that not all of the [2-14C]L-glycine was used for heme synthesis and converted to 14CO, because of a possible incorporation of this amino acid into proteins.
We also found that pretreatment of animals with ZnPPIX alone (or L-NAME alone) suppressed the increase in aortic cGMP levels at 1 day after surgery. A recent report showed that in normal conditions, ZnPPIX may have a nonselective effect in inhibiting the activity of NOS enzymes and soluble guanylate cyclase.46 In our experiments conducted at 1 day after surgery, when HO-1 is highly upregulated, ZnPPIX alone (or L-NAME alone) prevented the increase in cGMP levels. However, cGMP did not fall below control values; accordingly, arterial blood pressure remained unchanged after the treatments. These results would suggest that under our experimental conditions, ZnPPIX (50 µmol/kg) inhibits preferentially heme oxygenase activity rather than guanylate cyclase. It has to be noted that at 1 day after surgery, only the simultaneous inhibition of the cNOS and heme oxygenase pathways (ie, L-NAME+ZnPPIX or hemoglobin+ZnPPIX treatment) resulted in a significant decrease in aortic cGMP below control levels; this effect was accompanied by a substantial increase in mean arterial pressure. These findings together would suggest the existence of a complementary action between NO and CO in the control of vascular tone; in other words, under conditions of elevated HO-1 expression, CO can compensate for decreased NO availability (ie, L-NAME or hemoglobin treatment) in activating guanylate cyclase, whereas by blocking heme oxygenase activity (ie, ZnPPIX treatment), intracellular cGMP levels would be nevertheless maintained by the continuous production of vascular NO. We also observed a lack of correlation between HO-1 induction and intracellular cGMP in hepatic and heart tissues; although these findings remain to be further elucidated, changes in cGMP content in those tissues may not be relevant to explain mechanisms controlling vasomotor tone.
The results reported in the present study imply that regulation of heme oxygenase activity and CO production in vascular and organ tissues may be as important as the modulation of the NOS pathways, particularly in clinical situations characterized by a pronounced tissue stress response, such as hemorrhagic and septic shock. A functional link between increased hepatic HO-1 expression after hemorrhage/resuscitation in anesthetized rats and vascular control in the hepatic portal circulation is in line with the work presented here.47 It is also of relevance that increased HO-1 expression has been detected in large blood vessels and small resistance arterioles after treatment of animals with endotoxin.48 This upregulation of HO-1 was present in both endothelial and smooth muscle cells and was associated with a significant in vivo hypotensive effect, which was reversed by administration of ZnPPIX. Recent studies from our group have also established that treatment of aortic rings with a potent inducer of HO-1 resulted in suppression of the contractile response to phenylephrine, an effect that was reversed by inhibitors of heme oxygenase but was unaffected by an inhibitor of cNOS.49
In summary, we provide in the present study the first in vivo evidence that mechanisms of blood pressure regulation after surgical stress involve the HO-1/CO pathway, emphasizing the importance of a versatile physiological role for heme oxygenase in addition to its established function in heme catabolism.
| Acknowledgments |
|---|
Received April 21, 1998; accepted July 20, 1998.
| References |
|---|
|
|
|---|
2.
Maines MD, Trakshel GM, Kutty RK. Characterization of
two constitutive forms of rat liver microsomal heme
oxygenase: only one molecular species of the enzyme is
inducible. J Biol Chem. 1986;261:411419.
3. Raju VS, Maines MD. Coordinated expression and mechanism of induction of HSP32 (heme oxygenase-1) mRNA by hyperthermia in rat organs. Biochim Biophys Acta. 1994;1217:273280.[Medline] [Order article via Infotrieve]
4. Yamaguchi T, Horio F, Hashizume T, Tanaka M, Ikeda S, Kakinuma A, Nakajima H. Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem Biophys Res Commun. 1995;214:1119.[Medline] [Order article via Infotrieve]
5. Abraham NG, Drummond GS, Lutton JD, Kappas A. The biological significance and physiological role of heme oxygenase. Cell Physiol Biochem. 1996;6:129168.
6.
Keyse SM, Tyrrell RM. Heme oxygenase is
the major 32-kDa stress protein induced in human skin fibroblasts by
UVA radiation, hydrogen peroxide, and sodium arsenite. Proc Natl
Acad Sci U S A. 1989;86:99103.
7. Choi AMK, Alam J. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol. 1996;15:919.[Abstract]
8.
Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames
BN. Bilirubin is an antioxidant of possible
physiological importance. Science. 1987;235:10431046.
9. Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517554.[Medline] [Order article via Infotrieve]
10.
Morris SM, Billiar TR. New insights into the regulation
of inducible nitric oxide synthesis. Am J Physiol. 1994;266:E829E839.
11. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524526.[Medline] [Order article via Infotrieve]
12.
Ignarro LJ, Buga GM, Wood KS.
Endothelium-derived relaxing factor produced and
released from artery and vein is nitric oxide. Proc Natl Acad Sci
U S A. 1987;84:92659269.
13.
Rees DD, Palmer RMJ, Moncada S. Role of
endothelium-derived nitric oxide in the regulation of
blood pressure. Proc Natl Acad Sci U S A. 1989;86:33753378.
14. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109142.[Medline] [Order article via Infotrieve]
15. Utz J, Ullrich V. Carbon monoxide relaxes ileal smooth muscle through activation of guanylate cyclase. Biochem Pharmacol. 1991;41:11951201.[Medline] [Order article via Infotrieve]
16.
Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH.
Carbon monoxide: a putative neural messenger. Science. 1993;259:381384.
17. Maines MD. Carbon monoxide: an emerging regulator of cGMP in the brain. Mol Cell Neurosci. 1993;4:389397.
18. Suematsu M, Goda N, Sano T, Kashiwagi S, Egawa T, Shinoda Y, Ishimura Y. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest. 1995;96:24312437.
19. Ingi T, Cheng J, Ronnett GV. Carbon-monoxide: an endogenous modulator of the nitric oxide-cyclic GMP signaling system. Neuron. 1996;16:835842.[Medline] [Order article via Infotrieve]
20.
Motterlini R, Foresti R, Intaglietta M, Winslow RM.
NO-mediated activation of heme oxygenase:
endogenous cytoprotection against oxidative stress to
endothelium. Am J Physiol. 1996;270:H107H114.
21.
Durante W, Kroll MH, Christodoulides N, Peyton KJ,
Schafer AI. Nitric oxide induces heme oxygenase-1 gene
expression and carbon monoxide production in vascular smooth
muscle cells. Circ Res. 1997;80:557564.
22.
Foresti R, Clark JE, Green CJ, Motterlini R. Thiol
compounds interact with nitric oxide in regulating heme
oxygenase-1 induction in endothelial cells.
Involvement of superoxide and peroxynitrite anions. J Biol
Chem. 1997;272:1841118417.
23.
Hartsfield CL, Alam J, Cook JL, Choi AMK. Regulation of
heme oxygenase-1 gene expression in vascular smooth muscle
cells by nitric oxide. Am J Physiol. 1997;273:L980L988.
24.
Kim YM, Bergonia HA, Muller C, Pitt BR, Watkins WD,
Lancaster JR Jr. Loss and degradation of enzyme-bound heme induced by
cellular nitric oxide synthesis. J Biol Chem. 1995;270:57105713.
25. Motterlini R, Hidalgo A, Sammut I, Shah KA, Mohammed S, Srai K, Green CJ. A precursor of the nitric oxide donor SIN-1 modulates the stress protein heme oxygenase-1 in rat liver. Biochem Biophys Res Commun. 1996;225:167172.[Medline] [Order article via Infotrieve]
26.
Johnson RA, Lavesa M, Askari B, Abraham NG, Nasjletti
A. A heme oxygenase product, presumably carbon
monoxide, mediates a vasodepressor function in rats.
Hypertension. 1995;25:166169.
27. Winslow RM, Chapman KW. Pilot-scale preparation of hemoglobin solutions. Methods Enzymol. 1994;231:316.[Medline] [Order article via Infotrieve]
28.
Martin W, Villani GM, Jothianandan D, Furchgott RF.
Selective blockade of endothelium-dependent and
glyceryl trinitrate-induced relaxation by hemoglobin and by methylene
blue in the rabbit aorta. J Pharmacol Exp Ther. 1985;232:708716.
29. Keipert PE, Gonzales A, Gomez CL, Macdonald VW, Hess JR, Winslow RM. Acute changes in systemic blood pressure and urine output of conscious rats following exchange transfusion with diaspirin-crosslinked hemoglobin solution. Transfusion. 1993;33:701708.[Medline] [Order article via Infotrieve]
30. Keipert PE, Gomez CL, Gonzales A, Macdonald VW, Hess JR, Winslow RM. Diaspirin cross-linked hemoglobin: tissue distribution and long-term excretion after exchange transfusion. J Lab Clin Med. 1994;123:701711.[Medline] [Order article via Infotrieve]
31. Zygmunt PM, Hogestatt ED, Grundemar L. Light-dependent effects of zinc protoporphyrin IX on endothelium-dependent relaxation resistant to N omega-nitro-L-arginine. Acta Physiol Scand. 1994;152:137143.[Medline] [Order article via Infotrieve]
32.
Maines MD, Kappas A. Cobalt induction of hepatic heme
oxygenase, with evidence that cytochrome P450 is not
essential for this enzyme activity. Proc Natl Acad Sci
U S A. 1974;71:42934297.
33. Vanzetti G. An azide-methemoglobin method for hemoglobin determination in blood. J Lab Clin Med. 1966;67:116126.[Medline] [Order article via Infotrieve]
34. Udelsman R, Blake MJ, Holbrook NJ. Molecular response to surgical stress: specific and simultaneous heat shock protein induction in the adrenal cortex, aorta, and vena cava. Surgery. 1991;110:11251131.[Medline] [Order article via Infotrieve]
35.
Rohlfs RJ, Bruner E, Chiu A, Gonzales A, Gonzales ML,
Magde D, Magde MD Jr, Vandegriff KD, Winslow RM. Arterial
blood pressure responses to cell-free hemoglobin solutions and the
reaction with nitric oxide. J Biol Chem. 1998;273:1212812134.
36.
Motterlini R, Foresti R, Intaglietta M, Vandegriff K,
Winslow RM. Oxidative-stress response in vascular
endothelial cells exposed to acellular hemoglobin
solutions. Am J Physiol. 1995;269:H648H655.
37. Motterlini R, Vandegriff K, Winslow R. Hemoglobin-NO interaction and its implications. Transfus Med Rev. 1996;10:7784.[Medline] [Order article via Infotrieve]
38.
Motterlini R, Macdonald VW. Cell-free hemoglobin
potentiates acetylcholine-induced coronary vasoconstriction in
rabbit hearts. J Appl Physiol. 1993;75:22242233.
39. Motterlini R. Interaction of hemoglobin with nitric oxide and carbon monoxide: physiological implications. In: Vandegriff K, Intaglietta M, Winslow RM, eds. Blood Substitutes: New Challenges. Boston, Mass: Birkauser; 1996:7498.
40.
Hess JR, Macdonald VW, Brinkley WW. Systemic and
pulmonary hypertension after resuscitation with cell-free
hemoglobin. J Appl Physiol. 1993;74:17691778.
41.
Sacerdoti D, Escalante B, Abraham NG, McGiff JC, Levere
RD, Schwartzman ML. Treatment with tin prevents the development of
hypertension in spontaneously hypertensive rats. Science. 1989;243:388390.
42.
Johnson RA, Lavesa M, Deseyn K, Scholer MJ, Nasjletti
A. Heme oxygenase substrates acutely lower blood pressure
in hypertensive rats. Am J Physiol. 1996;271:H1132H1138.
43. Maulik N, Engelman DT, Watanabe M, Engelman RM, Rousou JA, Flack JE, Deaton DW, Gorbunov NV, Elsayed NM, Kagan VE, Das DK. Nitric oxide/carbon monoxide: a molecular switch for myocardial preservation during ischemia. Circulation. 1996;94(suppl II):II-398II-406.
44.
Morita T, Perrella MA, Lee ME, Kourembanas S. Smooth
muscle cell-derived carbon monoxide is a regulator of vascular cGMP.
Proc Natl Acad Sci U S A. 1995;92:14751479.
45. Marks GS, Brien JF, Nakatsu K, McLaughlin BE. Does carbon monoxide have a physiological function? Trends Pharmacol Sci. 1991;12:185188.[Medline] [Order article via Infotrieve]
46.
Zakhary R, Gaine SP, Dinerman JL, Ruat M, Flavahan NA,
Snyder SH. Heme oxygenase 2: endothelial
and neuronal localization and role in
endothelium-dependent relaxation. Proc Natl Acad
Sci U S A. 1996;93:795798.
47.
Bauer M, Pannen BHJ, Bauer I, Herzog C, Wanner GA,
Hanselmann R, Zhang JX, Clemens MG, Larsen R. Evidence for a
functional-link between stress-response and vascular control in hepatic
portal circulation. Am J Physiol. 1996;271:G929G935.
48.
Yet SF, Pellacani A, Patterson C, Tan L, Folta SC,
Foster L, Lee WS, Hsieh CM, Perrella MA. Induction of heme
oxygenase-1 expression in vascular smooth muscle cells: a
link to endotoxic shock. J Biol Chem. 1997;272:42954301.
49. Sammut I, Foresti R, Green CJ, Motterlini R. Involvement of the heme oxygenase/carbon monoxide pathway in the suppression of acute pressor responses in rat aortic rings [abstract]. Br J Pharmacol. 1997;122:P194.
This article has been cited by other articles:
![]() |
M. H. Zaki, S. Fujii, T. Okamoto, S. Islam, S. Khan, K. A. Ahmed, T. Sawa, and T. Akaike Cytoprotective Function of Heme Oxygenase 1 Induced by a Nitrated Cyclic Nucleotide Formed during Murine Salmonellosis J. Immunol., March 15, 2009; 182(6): 3746 - 3756. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. K. Idriss, A. D. Blann, and G. Y.H. Lip Hemoxygenase-1 in Cardiovascular Disease J. Am. Coll. Cardiol., September 16, 2008; 52(12): 971 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham and A. Kappas Pharmacological and Clinical Aspects of Heme Oxygenase Pharmacol. Rev., March 1, 2008; 60(1): 79 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yang, P. J. Lee, L. Long, R. C. Trembath, and N. W. Morrell BMP4 Induces HO-1 via a Smad-Independent, p38MAPK-Dependent Pathway in Pulmonary Artery Myocytes Am. J. Respir. Cell Mol. Biol., November 1, 2007; 37(5): 598 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hill-Kapturczak and A. Agarwal Haem oxygenase-1--a culprit in vascular and renal damage? Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1495 - 1499. [Full Text] [PDF] |
||||
![]() |
M. Bolognesi, D. Sacerdoti, A. Piva, M. Di Pascoli, F. Zampieri, S. Quarta, R. Motterlini, P. Angeli, C. Merkel, and A. Gatta Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium Channels Contributes to Mesenteric Vasodilatation in Cirrhotic Rats J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 187 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tanaka, J. M. Maher, C. Chen, and C. D. Klaassen Hepatic Ischemia-Reperfusion Induces Renal Heme Oxygenase-1 via NF-E2-Related Factor 2 in Rats and Mice Mol. Pharmacol., March 1, 2007; 71(3): 817 - 825. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hirakawa and Y. Hayashida Autonomic Cardiovascular Responses to Heme Oxygenase Inhibition in Conscious Rats Hypertension, December 1, 2006; 48(6): 1124 - 1129. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sawle, J. Hammad, I. J. S. Fairlamb, B. Moulton, C. T. O'Brien, J. M. Lynam, A. K. Duhme-Klair, R. Foresti, and R. Motterlini Bioactive Properties of Iron-Containing Carbon Monoxide-Releasing Molecules J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 403 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tayem, T. R. Johnson, B. E. Mann, C. J. Green, and R. Motterlini Protection against cisplatin-induced nephrotoxicity by a carbon monoxide-releasing molecule Am J Physiol Renal Physiol, April 1, 2006; 290(4): F789 - F794. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rebel, S. Cao, H. Kwansa, S. Dore, E. Bucci, and R. C. Koehler Dependence of acetylcholine and ADP dilation of pial arterioles on heme oxygenase after transfusion of cell-free polymeric hemoglobin Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1027 - H1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Poole, W. Wang, Y.-C. Chen, E. Zolty, S. Falk, A. Mitra, and R. Schrier Role of heme oxygenase-1 in endotoxemic acute renal failure Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1382 - F1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Bolognesi, D Sacerdoti, M Di Pascoli, P Angeli, S Quarta, A Sticca, P Pontisso, C Merkel, and A Gatta Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites Gut, November 1, 2005; 54(11): 1630 - 1636. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Morita Heme Oxygenase and Atherosclerosis Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1786 - 1795. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Lam, S. J. Getting, and M. Perretti In Vitro and In Vivo Induction of Heme Oxygenase 1 in Mouse Macrophages following Melanocortin Receptor Activation J. Immunol., February 15, 2005; 174(4): 2297 - 2304. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Fujimoto, M. Ohno, S. Ayabe, H. Kobayashi, N. Ishizaka, H. Kimura, K.-i. Yoshida, and R. Nagai Carbon Monoxide Protects Against Cardiac Ischemia--Reperfusion Injury In Vivo via MAPK and Akt--eNOS Pathways Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1848 - 1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tongers, B. Fiedler, D. Konig, T. Kempf, G. Klein, J. Heineke, T. Kraft, S. Gambaryan, S. M Lohmann, H. Drexler, et al. Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes Cardiovasc Res, August 15, 2004; 63(3): 545 - 552. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-M. Hu, Y.-H. Chen, M.-T. Chiang, and L.-Y. Chau Heme Oxygenase-1 Inhibits Angiotensin II-Induced Cardiac Hypertrophy In Vitro and In Vivo Circulation, July 20, 2004; 110(3): 309 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guo, A. B. Stein, W.-J. Wu, W. Tan, X. Zhu, Q.-H. Li, B. Dawn, R. Motterlini, and R. Bolli Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1649 - H1653. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Clark, P. Naughton, S. Shurey, C. J. Green, T. R. Johnson, B. E. Mann, R. Foresti, and R. Motterlini Cardioprotective Actions by a Water-Soluble Carbon Monoxide-Releasing Molecule Circ. Res., July 25, 2003; 93 (2): e2 - e8. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Mayer, X. Wang, and M. D. Maines Nitric Oxide Inhibitor N{omega}-Nitro-L-arginine Methyl Ester Potentiates Induction of Heme Oxygenase-1 in Kidney Ischemia/Reperfusion Model: A Novel Mechanism for Regulation of the Oxygenase J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 43 - 50. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Naik and B. R. Walker Heme oxygenase-mediated vasodilation involves vascular smooth muscle cell hyperpolarization Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H220 - H228. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Ndisang, L. Wu, W. Zhao, and R. Wang Induction of heme oxygenase-1 and stimulation of cGMP production by hemin in aortic tissues from hypertensive rats Blood, May 15, 2003; 101(10): 3893 - 3900. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Chen, S.-F. Yet, and M. A. Perrella Role of Heme Oxygenase-1 in the Regulation of Blood Pressure and Cardiac Function Exp Biol Med, May 1, 2003; 228(5): 447 - 453. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Masini, A. Vannacci, C. Marzocca, S. Pierpaoli, L. Giannini, O. Fantappie, R. Mazzanti, and P. F. Mannaioni Heme Oxygenase-1 and the Ischemia-Reperfusion Injury in the Rat Heart Exp Biol Med, May 1, 2003; 228(5): 546 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Naik, T. L. O'Donaughy, and B. R. Walker Endogenous carbon monoxide is an endothelial-derived vasodilator factor in the mesenteric circulation Am J Physiol Heart Circ Physiol, March 1, 2003; 284(3): H838 - H845. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Naughton, R. Foresti, S. K. Bains, M. Hoque, C. J. Green, and R. Motterlini Induction of Heme Oxygenase 1 by Nitrosative Stress. A ROLE FOR NITROXYL ANION J. Biol. Chem., October 18, 2002; 277(43): 40666 - 40674. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Samb, C. Taille, A. Almolki, J. Megret, J. M. Staddon, M. Aubier, and J. Boczkowski Heme oxygenase modulates oxidant-signaled airway smooth muscle contractility: role of bilirubin Am J Physiol Lung Cell Mol Physiol, September 1, 2002; 283(3): L596 - L603. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Ndisang, W. Zhao, and R. Wang Selective Regulation of Blood Pressure by Heme Oxygenase-1 in Hypertension Hypertension, September 1, 2002; 40(3): 315 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Peyton, S. V. Reyna, G. B. Chapman, D. Ensenat, X.-m. Liu, H. Wang, A. I. Schafer, and W. Durante Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth Blood, May 29, 2002; 99(12): 4443 - 4448. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Scapagnini, R. Foresti, V. Calabrese, A. M. G. Stella, C. J. Green, and R. Motterlini Caffeic Acid Phenethyl Ester and Curcumin: A Novel Class of Heme Oxygenase-1 Inducers Mol. Pharmacol., March 1, 2002; 61(3): 554 - 561. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Motterlini, J. E. Clark, R. Foresti, P. Sarathchandra, B. E. Mann, and C. J. Green Carbon Monoxide-Releasing Molecules: Characterization of Biochemical and Vascular Activities Circ. Res., February 8, 2002; 90 (2): e17 - e24. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Naik and B. R. Walker Homogeneous segmental profile of carbon monoxide-mediated pulmonary vasodilation in rats Am J Physiol Lung Cell Mol Physiol, December 1, 2001; 281(6): L1436 - L1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ishikawa, D. Sugawara, J. Goto, Y. Watanabe, K. Kawamura, M. Shiomi, H. Itabe, and Y. Maruyama Heme Oxygenase-1 Inhibits Atherogenesis in Watanabe Heritable Hyperlipidemic Rabbits Circulation, October 9, 2001; 104(15): 1831 - 1836. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Park, C. Metais, H. B. Dai, M. E. Comunale, and F. W. Sellke Microvascular Endothelial Dysfunction and its Mechanism in a Rat Model of Subarachnoid Hemorrhage Anesth. Analg., April 1, 2001; 92(4): 990 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sato, J. Balla, L. Otterbein, R. N. Smith, S. Brouard, Y. Lin, E. Csizmadia, J. Sevigny, S. C. Robson, G. Vercellotti, et al. Carbon Monoxide Generated by Heme Oxygenase-1 Suppresses the Rejection of Mouse-to-Rat Cardiac Transplants J. Immunol., March 15, 2001; 166(6): 4185 - 4194. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Nath, J. P. Grande, J. J. Haggard, A. J. Croatt, Z. S. Katusic, A. Solovey, and R. P. Hebbel Oxidative Stress and Induction of Heme Oxygenase-1 in the Kidney in Sickle Cell Disease Am. J. Pathol., March 1, 2001; 158(3): 893 - 903. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Liu, D. Song, and S. S. Lee Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat Am J Physiol Gastrointest Liver Physiol, January 1, 2001; 280(1): G68 - G74. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wang, Z. Wang, L. Wu, S. T. Hanna, and R. Peterson-Wakeman Reduced Vasorelaxant Effect of Carbon Monoxide in Diabetes and the Underlying Mechanisms Diabetes, January 1, 2001; 50(1): 166 - 174. [Abstract] [Full Text] |
||||
![]() |
L. E. Otterbein and A. M. K. Choi Heme oxygenase: colors of defense against cellular stress Am J Physiol Lung Cell Mol Physiol, December 1, 2000; 279(6): L1029 - L1037. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. O'Donaughy and B. R. Walker Renal vasodilatory influence of endogenous carbon monoxide in chronically hypoxic rats Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2908 - H2915. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ishizaka, T. Aizawa, I. Mori, J.-I. Taguchi, Y. Yazaki, R. Nagai, and M. Ohno Heme oxygenase-1 is upregulated in the rat heart in response to chronic administration of angiotensin II Am J Physiol Heart Circ Physiol, August 1, 2000; 279(2): H672 - H678. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. G. Abraham, S. Jiang, L. Yang, B. A. Zand, M. Laniado-Schwartzman, J. Marji, G. S. Drummond, and A. Kappas Adenoviral Vector-Mediated Transfer of Human Heme Oxygenase in Rats Decreases Renal Heme-Dependent Arachidonic Acid Epoxygenase Activity J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 494 - 500. [Abstract] [Full Text] |
||||
![]() |
R. Motterlini, R. Foresti, R. Bassi, V. Calabrese, J. E. Clark, and C. J. Green Endothelial Heme Oxygenase-1 Induction by Hypoxia. MODULATION BY INDUCIBLE NITRIC-OXIDE SYNTHASE AND S-NITROSOTHIOLS J. Biol. Chem., April 28, 2000; 275(18): 13613 - 13620. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Clark, R. Foresti, P. Sarathchandra, H. Kaur, C. J. Green, and R. Motterlini Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2000; 278(2): H643 - H651. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Galbraith Heme Oxygenase: Who Needs It? Exp Biol Med, December 1, 1999; 222(3): 299 - 305. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Maines, V. S. Raju, and N. Panahian Spin Trap (N-t-butyl-alpha -phenylnitrone)-Mediated Suprainduction of Heme Oxygenase-1 in Kidney Ischemia/Reperfusion Model: Role of the Oxygenase in Protection against Oxidative Injury J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 911 - 919. [Abstract] [Full Text] |
||||
![]() |
W. Durante, K. J. Peyton, and A. I. Schafer Platelet-Derived Growth Factor Stimulates Heme Oxygenase-1 Gene Expression and Carbon Monoxide Production in Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, November 1, 1999; 19(11): 2666 - 2672. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. A. D. T. G. Wagener, J.-L. da Silva, T. Farley, T. de Witte, A. Kappas, and N. G. Abraham Differential Effects of Heme Oxygenase Isoforms on Heme Mediation of Endothelial Intracellular Adhesion Molecule 1 Expression J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 416 - 423. [Abstract] [Full Text] |
||||
![]() |
F. Kozma, R. A. Johnson, F. Zhang, C. Yu, X. Tong, and A. Nasjletti Contribution of endogenous carbon monoxide to regulation of diameter in resistance vessels Am J Physiol Regulatory Integrative Comp Physiol, April 1, 1999; 276(4): R1087 - R1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C.M. Siow, H. Sato, and G. E. Mann Heme oxygenase-carbon monoxide signalling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide? Cardiovasc Res, February 1, 1999; 41(2): 385 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Motterlini, J. E. Clark, R. Foresti, P. Sarathchandra, B. E. Mann, and C. J. Green Carbon Monoxide-Releasing Molecules: Characterization of Biochemical and Vascular Activities Circ. Res., February 8, 2002; 90 (2): e17 - e24. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |